Zenosense, Inc. (ZENO) Prepares to Sniff Out MRSA
Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that’s associated with several dangerous infections. Particularly troublesome in nursing homes, hospitals and prisons, MRSA is difficult to treat with standard types of antibiotics and, therefore, more dangerous than other bacterial strains. While time intensive cultures have traditionally been used to diagnose the infections, quicker tools are needed to adequately prevent the spread of the bacteria and minimize treatment costs. Zenosense, Inc. (OTCQB: ZENO), through the development of its low-cost electronic “nose” device, is working to revolutionize the market.
By using a low cost gas sensor as a starting point, Zenosense is developing an affordable diagnostic tool that acts like a smoke alarm for MRSA. The sensor will continuously scan the air for infection-specific volatile organic compounds (VOC), which will provide administrators with immediate feedback that should be more effective in containing MRSA outbreaks.
According to the CDC, MRSA infections impact an estimated 75,000 people annually. While these patients generally have a high survivability rate, the infections can be particularly dangerous if compounded with other health problems. For that reason, it is imperative for healthcare facilities to detect outbreaks of MRSA in their early stages in order to limit their spread. Late detection of MRSA outbreaks has significant costs and dangers. Through the use of the company’s specialized detection device, hospitals will be able to improve their probability of early detection, which will open the door for proactive protective measures and significantly reduced costs.
While electronic “nose” devices currently exist on the market, they are too bulky and expensive for widespread use in medical facilities. Zenosense, through the continued development of its detection device, is preparing to service a multi-billion dollar industry while addressing substantial health and safety concerns.
The company’s MRSA device is intended to be produced in both wearable and fixed position forms. With the company continuing towards the completion of development, look for Zenosense to make significant waves in the diagnostic and detection industry in the years to come.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that’s associated with several dangerous infections. Particularly troublesome in nursing homes, hospitals and prisons, MRSA is difficult to treat with standard types of antibiotics and, therefore, more dangerous than other bacterial strains. While time intensive cultures have traditionally been used to diagnose the infections, quicker tools are needed to adequately prevent the spread of the bacteria and minimize treatment costs. Zenosense, Inc. (OTCQB: ZENO), through the development of its low-cost electronic “nose” device, is working to revolutionize the market.
By using a low cost gas sensor as a starting point, Zenosense is developing an affordable diagnostic tool that acts like a smoke alarm for MRSA. The sensor will continuously scan the air for infection-specific volatile organic compounds (VOC), which will provide administrators with immediate feedback that should be more effective in containing MRSA outbreaks.
According to the CDC, MRSA infections impact an estimated 75,000 people annually. While these patients generally have a high survivability rate, the infections can be particularly dangerous if compounded with other health problems. For that reason, it is imperative for healthcare facilities to detect outbreaks of MRSA in their early stages in order to limit their spread. Late detection of MRSA outbreaks has significant costs and dangers. Through the use of the company’s specialized detection device, hospitals will be able to improve their probability of early detection, which will open the door for proactive protective measures and significantly reduced costs.
While electronic “nose” devices currently exist on the market, they are too bulky and expensive for widespread use in medical facilities. Zenosense, through the continued development of its detection device, is preparing to service a multi-billion dollar industry while addressing substantial health and safety concerns.
The company’s MRSA device is intended to be produced in both wearable and fixed position forms. With the company continuing towards the completion of development, look for Zenosense to make significant waves in the diagnostic and detection industry in the years to come.
For more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
